menu
    • menu
    [{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Ranibizumab","moa":"VEGFA","graph1":"Ophthalmology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intravitreal Injection","sponsorNew":"STADA Arzneimittel \/ BAUSCH + LOMB","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ BAUSCH + LOMB"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Lobsor Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"STADA Arzneimittel \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"PharmaMar","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Trabectedin","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Etilevodopa","moa":"D3 receptor","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"D","therapeuticArea":"Nephrology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.12,"dosageForm":"Modified-release Capsule","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel AG","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel AG"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Crescita Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Lidocaine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"STADA Arzneimittel \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Dermatology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ STADA","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Calliditas Therapeutics AB","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Budesonide","moa":"Glucocorticoid receptor","graph1":"Nephrology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Modified Release Capsule","sponsorNew":"STADA Arzneimittel \/ Calliditas Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Calliditas Therapeutics"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"ICELAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ICELAND","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Adalimumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Xbrane Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ranibizumab","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"STADA Arzneimittel \/ Xbrane Biopharma","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Xbrane Biopharma"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ Not Applicable"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Injection","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Bio-Thera Solutions","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Gollmumab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.16,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"ICELAND","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Denosumab","moa":"","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ STADA Arzneimittel","highestDevelopmentStatusID":"10","companyTruncated":"STADA Arzneimittel \/ STADA Arzneimittel"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Alvotech","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Technology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Alvotech","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Alvotech"},{"orgOrder":0,"company":"STADA Arzneimittel","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Budesonide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"STADA Arzneimittel","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"STADA Arzneimittel \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"STADA Arzneimittel \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by STADA Arzneimittel

    Menu

    STADA Arzneimittel

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Budesonide

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calliditas’ STADA Receives EC Decision for Full Approval of Kinpeygo® in IgA Nephropathy

                            Details : Kinpeygo (budesonide)is a modified-release capsule, glucocorticoid receptor agonist, which is indicated for the treatment of patients with primary IgA nephropathy.

                            Brand Name : Kinpeygo

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 26, 2024

                            Lead Product(s) : Budesonide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            STADA and Alvotech Launch Uzpruvo, First Ustekinumab Biosimilar to Stelara in Europe

                            Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.

                            Brand Name : Uzpruvo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 22, 2024

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Alvotech and STADA Add to Strategic Alliance Through Denosumab Partnership

                            Details : The partnership aims to cover AVT03, a clinical-stage biosimilar candidate referencing the Prolia®/Xgeva® (denosumab) medicines for osteoporosis and cancer-related bone loss respectively.

                            Brand Name : AVT03

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : Denosumab

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Recipient : Alvotech

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Gollmumab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : $157.5 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Bio-Thera and STADA Reach Agreement for BAT2506 Biosimilar in the EU and UK

                            Details : Under the agreement, Bio-Thera Solutions will maintain responsibility for development, manufacturing, and supply of BAT2506, a biosimilar candidate to Simponi® (golimumab).

                            Brand Name : BAT2506

                            Molecule Type : Large molecule

                            Upfront Cash : $10.0 million

                            May 28, 2024

                            Lead Product(s) : Gollmumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : Bio-Thera Solutions

                            Deal Size : $157.5 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            STADA and Alvotech Secure Approval for Uzpruvo, Europe's First Ustekinumab Biosimilar

                            Details : Uzpruvo (ustekinumab-biosimilar) is a human IgG1κ monoclonal antibody (mAb) which inhibits IL-12 & Il-23. It is approved by EMA for the treatment of crohn’s disease, psoriasis and psoriatic arthritis.

                            Brand Name : Uzpruvo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 10, 2024

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

                            Details : Uzpruvo (ustekinumab) biosimilar candidate to Stelara is a human IgG1κ monoclonal antibody (mAb), which is investigated for the treatment of moderate to severe chronic plaque-type psoriasis.

                            Brand Name : Uzpruvo

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 10, 2023

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Xbrane Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Stada and Xbrane Obtain British Approval for Ximluci® (ranibizumab) Biosimilar Referencing Lucentis®

                            Details : Ximluci (ranibizumab) binds and inhibits VEGF-A, including VEGF110, preventing the interaction of VEGF-A with VEGFR1 and VEGFR2 on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation...

                            Brand Name : Ximluci

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 16, 2023

                            Lead Product(s) : Ranibizumab

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Xbrane Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Recipient : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alvotech and STADA Broaden Access to Hukyndra® Adalimumab Biosimilar in Europe

                            Details : Hukyndra (adalimumab) is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor. Adalimumab is first product launched through an exclusive strategic partnership announced by Alvotech and STADA in November 2019...

                            Brand Name : Hukyndra

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 07, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Recipient : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Recipient : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

                            Details : Hukyndra (adalimumab), Hukyndra is a monoclonal antibody and a biosimilar to Humira® (adalimumab) that inhibits tumor necrosis factor, increases availability of high-concentration, low-volume, citrate-free presentations of adalimumab.

                            Brand Name : Hukyndra

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 22, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Recipient : Alvotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            STADA Arzneimittel

                            Germany arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Budesonide

                            Therapeutic Area : Nephrology

                            Study Phase : Approved

                            Sponsor : Calliditas Therapeutics AB

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Calliditas' Partner Stada Launches The First Medicine Authorized In The EU For Treating Primary Iga Nephropath...

                            Details : Nefecon (budesonide) is a patented novel, investigational oral formulation of a potent and well-known active substance – budesonide – for targeted release. The formulation is designed to deliver the drug to the ileum where the Peyer’s patches are c...

                            Brand Name : Nefecon

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 20, 2022

                            Lead Product(s) : Budesonide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Approved

                            Sponsor : Calliditas Therapeutics AB

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth